Table 2.
Comparison of demographic and clinical characteristics of patients with and without sarcopenia.
| With Sarcopenia | Without Sarcopenia | p-value | |
|---|---|---|---|
| Case number | 48 | 134 | |
| Age (years) | 66.6 ± 10.2 | 57.0 ± 11.7 | <0.001 |
| Male (%) | 24(50%) | 82(61%) | 0.232 |
| Body mass index (kg/m2) | 25.9 ± 4.1 | 23.8 ± 3.2 | <0.001 |
| Type 2 DM (%) | 18(38%) | 22(16%) | 0.004 |
| Synchronous (%) | 27(56%) | 92(69%) | 0.157 |
| Neoadjuvant chemotherapy | 10 (21%) | 25 (19%) | 0.831 |
| Adjuvant chemotherapy | 43 (90%) | 123 (92%) | 0.767 |
| Right-sided primary tumor (%) | 6(13%) | 22(16%) | 0.644 |
| Tumor stage T3, 4 (%) | 41(85%) | 116(87%) | 0.811 |
| Nodal status N2 (%) | 10 (21%) | 35(26%) | 0.560 |
| Main tumor (cm) | 4.1 ± 2.3 | 3.8 ± 2.5 | 0.453 |
| Tumor number >3 (%) | 14(29%) | 49(37%) | 0.382 |
| CEA (ng/ml) | 356 ± 1412 | 114 ± 571 | 0.102 |
| AST (U/L) | 28 ± 14 | 29 ± 13 | 0.575 |
| ALT (U/L) | 22 ± 12 | 29 ± 23 | 0.153 |
| Albumin (g/dl) | 3.9 ± 0.8 | 4.1 ± 0.5 | 0.072 |
| Platelet (103/μL) | 305 ± 124 | 295 ± 102 | 0.601 |
| NLR | 3.5 ± 3.4 | 2.7 ± 1.7 | 0.026 |
Data are expressed as mean±standard deviation or number (percentage).
Abbreviation: DM, diabetes mellitus; CEA, carcinoembryonic antigen; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.